Statistical issues in toxicokinetic modeling: A Bayesian perspective

Environmental Health Perspectives

Volumn 108, Issue SUPPL. 5, 2000, Pages 883-893

  Bernillon, Pascale ^a   Bois, Fréd́ric Y ^b,c  

^a INSERM   (France)

^b INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

^c Parc ALATA   (France)

Author keywords

Bayesian analysis; Hierarchical models; MCMC methods; Toxicokinetic models; Uncertainty; Variability

Indexed keywords

ARTICLE; BAYES THEOREM; CALIBRATION; CONCENTRATION RESPONSE; DRUG METABOLISM; ENVIRONMENTAL EXPOSURE; OCCUPATIONAL EXPOSURE; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SPECIES DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL MODEL; SYSTEM ANALYSIS; TOXICITY TESTING; TOXICOKINETICS;

EID: 0033674734     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.2307/3454322     Document Type: Article

References (119)

1. Biomarkers as tools in human health risk assessment
2. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H.A. Clowes Memorial Lecture
3. Mechanisms of carcinogenesis: Dose response
4. Implication of nonlinear kinetics on risk estimation in carcinogenesis
5. Risk assessment of carcinogenic and noncarcinogenic chemicals
6. A general scheme for the incorporation of pharmacokinetics in low-dose risk estimation for chemical carcinogenesis: Example-vinyl chloride
7. Pharmacokinetics and Risk Assessment
8. Implementation of EPA Revised Cancer Assessment Guidelines: Incorporation of Mechanistic and Pharmacokinetic Data
9. An introduction to the use of physiologically based pharmacokinetic models in risk assessment
10. Pharmacokinetic modeling approaches for describing the uptake, systemic distribution, and disposition of inhaled chemicals
11. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride
12. A trichloroethylene risk assessment using a Monte Carlo analysis of parameter uncertainty in conjunction with physiologically-based pharmacokinetic modeling
13. Effects of the structure of a toxicokinetic model of butadiene inhalation exposure on computed production of carcinogenic intermediates
14. Interspecies extrapolation of physiological pharmacokinetic parameter distributions
15. 1,3-Butadiene working group report
16. A parallelogram approach for safety evaluation of ingested acetaldehyde
17. Achieving credibility in risk assessment models
18. Variability of safe dose estimates when using complicated models of the carcinogenic process
19. Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output
20. Precision and sensitivity of pharmacokinetic models for cancer risk assessment: Tetrachloroethylene in mice, rats, and humans
21. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform
22. Structure and parameterization of pharmacokinetic models: Their impact on model predictions
23. Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE)
24. Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results
25. Uncertainty, variability, and sensitivity analysis in physiological pharmacokinetic models
26. Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation
27. Assessing, accommodating, and interpreting the influences of heterogeneity
28. Uncertainty in fitted estimates of apparent in vivo metabolic constants for chloroform
29. Physiological pharmacokinetic modelling
30. Trichloroethylene exposure - Simulation of uptake, excretion, and metabolism using a mathematical model
31. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans
32. Human styrene exposure - V. Development of a model for biological monitoring
33. Physiological pharmacokinetic models: Principles, applications, limitations and outlook
34. A physiologically based pharmacokinetic model for methyl mercury in the pregnant rat and fetus
35. The importance of anatomical realism for validation of physiological models of disposition of inhaled toxicants
36. Population toxicokinetics of tetrachloroethylene
37. Physiological pharmacokinetic analysis using population modeling and informative prior distributions
38. A physiological model of the pharmacokinetics of methylene chloride in B6C3F1 mice following I.V. administrations
39. Comparison of the pharmacokinetics of several polychlorinated biphenyls in mouse, rat, dog, and monkey by means of a physiological pharmacokinetic model
40. Physiologically based pharmacokinetic modeling of inhaled 2-butoxyethanol in man
41. A physiologically based pharmacokinetic assessment of tetrachloroethylene in groundwater for a bathing and showering determination
42. A distributed parameter physiologically-based pharmacokinetic model for dermal and inhalation exposure to volatile organic compounds
43. Effect of physical exercise on uptake, distribution and elimination of vapors in man
44. A physiologically based kinetic model of rat and mouse gestation: Disposition of a weak acid
45. A physiologically based pharmacokinetic computer model for human pregnancy
46. Physiologically based pharmacokinetic models in developmental toxicology
47. Development of a physiologically based pharmacokinetic model describing 2-methoxyacetic acid disposition in the pregnant mouse
48. Incorporation of temporal factors into physiologically based kinetic models for risk assessment
49. Physiologically based pharmacokinetic models applicable to organogenesis: Extrapolation between species and potential use in prenatal toxicity risk assessments
50. A computer model and program for xenobiotic disposition during pregnancy
51. An inhalation distribution model for the lactating mother and nursing child
52. Lactational transfer of tetrachloroethylene in rats
53. Estimation of occupational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin using a minimal physiologic toxicokinetic model
54. Quantitative relations in the physiological constitution of mammals
55. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
56. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm
57. Biological basis for extrapolation across mammalian species
58. Man versus beast: Pharmacokinetic scaling in mammals
59. Interspecies scaling and comparisons in drug development and toxicokinetics
60. Parameter and structural identifiability concepts and ambiguities; a critical review and analysis
61. Identifiability: The first step in parameter estimation
62. Parameter estimation: Local identifiability of parameters
63. Identifiability and indistinguishability of nonlinear pharmacokinetic models
64. Structural identifiability of PBPK models: Practical consequences for modeling strategies and study designs
65. A comparison of techniques for the estimation of model prediction uncertainty
66. Understanding uncertainty
67. Optimal statistical design for toxicokinetic studies
68. Optimal design for a study of butadiene toxicokinetics in humans
69. Methodology of population pharmacokinetics
70. Population models
71. The effect of neglecting correlations when propagating uncertainty and estimating the population distribution of risk
72. Modeling benzene pharmacokinetics across three sets of animal data: Parametric sensitivity and risk implications
73. Sensitivity analysis for physiologically based pharmacokinetic models
74. Propagation of uncertainty in risk assessments: The need to distinguish between uncertainty due to lack of knowledge and uncertainty due to variability
75. Estimating population kinetics
76. The population approach to pharmacokinetic data analysis: Rationale and standard data analysis methods
77. Population pharmacokinetic/pharmacodynamic methodology and applications: A bibliography
78. Population toxicokinetic of benzene
79. Variability in biological monitoring of solvent exposure. I: Development and validation of a population model
80. Variability in biological monitoring of organic solvent exposure. I: Application of a population physiological model
81. Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine
82. Nonparametric EM algorithms for estimating prior distributions
83. Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine
84. A maximum likelihood estimation method for random coefficient regression models
85. Nonlinear mixed effects models for repeated measures data
86. A Bayesian approach to nonlinear random effects models
87. Bayesian analysis of linear and non-linear population models by using the Gibbs sampler
88. An introduction to bayesian methods in health technology assessment
89. Local computations with probabilities on graphical structures and their application to expert systems
90. Causal diagrams for empirical research (with discussion)
91. Markov chain Monte Carlo methods in biostatistics
92. Kinetics of tetrachlorothylene in volunteers; Influence of exposure concentration and work load
93. Some remarks on noninformative priors
94. The selection of prior distributions by formal rules
95. Bayesian computational methods
96. Inference from Iterative Simulation Using Multiple Sequences
97. Markov chain Monte Carlo convergence diagnostics: A comparative review
98. Annealing Markov chain Monte Carlo with applications to ancestral inference
99. Strategies for improving MCMC
100. Some adaptive Monte Carlo methods for Bayesian inference
101. Structured Monte Carlo Markov chains
102. Pharmacokinetic models in the development of exposure indicators in epidemiology
103. The Bayesian modeling of covariates for population pharmacokinetic models
104. Analysis of PBPK models for risk characterization
105. Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics